Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
Ronald F Van VollenhovenBevra H HahnGeorge C TsokosPeter LipskyKaiyin FeiRobert M GordonIrene GreganKim Hung LoMarc ChevrierShawn RosePublished in: Arthritis & rheumatology (Hoboken, N.J.) (2020)
Ustekinumab provided sustained clinical benefit in patients with SLE through 1 year, with a safety profile consistent with other indications.